Drug Trial Radar · NCT03836716
Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial
Last checked: Nov 19, 2026Latest source record: Aug 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
120
Actual
Start
Sep 19, 2019
Primary completion
Jul 2, 2021
Study completion Jul 2, 2021
Sponsor
- Lead sponsor
- ZevraDenmarkIndustry
- Sponsor type
- Industry
- First posted
- Feb 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, non-randomized, open label trial, to assess long term safety and efficacy of Arimoclomol in subjects with Amyotrophic Lateral Sclerosis (ALS) who have completed the ORARIALS-01 trial.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
ArimoclomolDrug
2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) Over the Open-label Treatment PeriodTime frame: From Day 1 in ORARIALS-02 to Early Termination, an average of approximately 28 weeks
- Mean and Change From Baseline in Clinical Safety Laboratory Tests - Hematology (1)Time frame: Week 76
- Mean and Change From Baseline in Clinical Safety Laboratory Tests - Hematology (2)Time frame: Week 76
- Mean and Change From Baseline in Clinical Safety Laboratory Tests - ErythrocytesTime frame: Week 76
- Mean and Change From Baseline in Clinical Safety Laboratory Tests - HematocritTime frame: Week 76
- Mean and Change From Baseline in Clinical Safety Laboratory Tests - HemoglobinTime frame: Week 76
- Mean and Change From Baseline in Clinical Safety Laboratory Tests - Clinical Chemistry (1)Time frame: Week 76
- Mean and Change From Baseline in Clinical Safety Laboratory Tests - Clinical Chemistry (2)Time frame: Week 76
- Mean and Change From Baseline in Clinical Safety Laboratory Tests - Clinical Chemistry (3)Time frame: Week 76
- Mean and Change From Baseline in Clinical Safety Laboratory Tests - Albumin and ProteinTime frame: Week 76
- Mean and Change From Baseline in Clinical Safety Laboratory Tests - Cystatin CTime frame: Week 76
- Mean and Change From Baseline in Vital Signs - Blood PressureTime frame: Week 76
- Mean and Change From Baseline in Vital Signs - Pulse RateTime frame: Week 76
- Mean and Change From Baseline in Vital Signs - Respiratory RateTime frame: Week 76
- Mean and Change From Baseline in Vital Signs - TemperatureTime frame: Week 76
- Number of Participants With Potentially Clinically Significant Abnormalities in Clinical Safety Laboratory Tests and Vital Signs Over the Open-label Treatment PeriodTime frame: From Day 1 in ORARIALS-02 to Early Termination, an average of approximately 28 weeks
- Columbia-Suicide Severity Rating Scale (C-SSRS) Over the Open-label Treatment PeriodTime frame: From Day 1 in ORARIALS-02 to Early Termination, an average of approximately 28 weeks
Locations
23 sites in 11 countries. Site status is shown where the registry gives one.
St. Joseph's Hospital and Medical Center (SJHMC) - Barrow Neurological Institute (BNI) - The Gregory W. Fulton ALS and Neuromuscular Disease Center
Phoenix, Arizona
UC Irvine Health ALS and Neuromuscular Center
Orange, California
University of Miami
Miami, Florida
Hospital for Special Surgery
New York, New York
Providence Brain & Spine Institute
Portland, Oregon
University of Pensylvania, Perelman Center for Advanced Medicine - Penn Neuroscience Center
Philadelphia, Pennsylvania
University of Virginia Health System
Charlottesville, Virginia
Catholic University Leuven
Leuven, Belgium
London Health Sciences Centre
London, Ontario, Canada
Centre Hospitalier Regional Universitaire (CHRU) Montpellier - Hopital Gui De Chauliac
Montpellier, France
Groupe Hospitalier Pitie-Salpetriere - Centre d'Investigation Clinique Neurosciences 1422
Paris, France
Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK) - Ambulanz fuer ALS und andere Motoneuronenerkrankungen
Berlin, Germany
Medizinische Hochschule Hannover (MHH) - Klinik fuer Neurologie
Hanover, Germany
Universitaetsklinikum Ulm - Klinik fuer Neurologie
Ulm, Germany
Instituti Clinica Scientifici Maugeri
Milan, Italy
Azienda Ospedaliero Universitaria (AUO) di Torino - Citta'della Salute e della Scienza di Torino
Torino, Italy
University Medical Center Utrecht
Utrecht, Netherlands
Centrum Medyczne NeuroProtect
Warsaw, Poland
Citi Clinic
Warsaw, Poland
Hospital Universitario Vall d'Hebron ALS Unit. Consultas Externas; Office: 9-10-11
Barcelona, Spain
Hospital Carlos III - Hospital Universitario La Paz, ALS Unit
Madrid, Spain
Umeå University Hospital
Umeå, Sweden
Leonard Wolfson Experimental Neurology Centre
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.